Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Seres Therapeutics (MCRB) Accumulated Depreciation & Amortization (2016 - 2025)

Seres Therapeutics' Accumulated Depreciation & Amortization history spans 10 years, with the latest figure at $56.4 million for Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization changed N/A year-over-year to $56.4 million; the TTM value through Sep 2025 reached $56.4 million, changed N/A, while the annual FY2023 figure was $49.1 million, 8.97% up from the prior year.
  • Accumulated Depreciation & Amortization for Q3 2025 was $56.4 million at Seres Therapeutics, up from $54.3 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $56.4 million in Q3 2025 and bottomed at $40.3 million in Q4 2021.
  • The 4-year median for Accumulated Depreciation & Amortization is $48.5 million (2023), against an average of $48.1 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization grew 17.33% in 2021 before it increased 8.97% in 2023.
  • A 4-year view of Accumulated Depreciation & Amortization shows it stood at $40.3 million in 2021, then rose by 11.85% to $45.0 million in 2022, then rose by 8.97% to $49.1 million in 2023, then rose by 14.87% to $56.4 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Accumulated Depreciation & Amortization are $56.4 million (Q3 2025), $54.3 million (Q1 2025), and $49.1 million (Q4 2023).